Mesoblast logo

MSB - Mesoblast News Story

A$2.58 -0.0  -0.4%

Last Trade - 5:10am

Sector
Healthcare
Size
Mid Cap
Market Cap £656.0m
Enterprise Value £698.3m
Revenue £17.1m
Position in Universe 229th / 1834

BUZZ-Australia's Mesoblast gains after submitting drug's clinical data to U.S. FDA

Fri 3rd January, 2020 1:37am
** Shares of Mesoblast Ltd  MSB.AX  rise as much as 5.9% to
A$2.170, hitting a one-week high
    ** The cellular medicine maker on Thursday submitted the
clinical efficacy and safety data for its drug remestemcel-L,
for the treatment of children with a type of graft versus host
disease (GVHD), which occurs on rejecting a transplant
    ** MSB says if the U.S. FDA approves the final version of
data to be filed in Jan, remestemcel-L is planned to be launched
in the United States in 2020
    ** ASX-listed stock had jumped 3.8% on Thursday after the
news, but closed 1.4% lower; later in the day, MSB's U.S.-listed
shares jumped 8.2% to an over one-year high  urn:newsml:reuters.com:*:nL4N297237
    ** Stock posts its biggest intraday pct gain since Dec. 18
    ** About 2.3 mln shares change hands, slightly higher
compared with the 30-day avg volume of 2.2 mln
    ** Stock had risen 79.3% in 2019, compared with a 19.1%
increase in the ASX All Ordinaries index  .AORD  

 (Reporting by Rashmi Ashok in Bengaluru)
 ((Rashmi.Ashok@thomsonreuters.com; +918067491689;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.